logo-loader
viewAdmedus Ltd

Admedus Ltd moving up the value chain and preparing for 'pivotal' year

Wayne Paterson, chief executive of Admedus Ltd (ASX:AHZ), spoke to Proactive's Andrew Scott following the release of their quarterly update.

It's a big week for Admedus with the launch of both CardioCel in India and CardioCel 3D in North America.

CardioCel is the company’s flagship product and is becoming a surgeon-preferred biomaterial for heart valve repair surgeries.

Quick facts: Admedus Ltd

Price: 0.09 AUD

ASX:AHZ
Market: ASX
Market Cap: $53.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read